Aktiechat - investeringstips

	21/11 16:02 af Jan Van de Winkel	Successful Capital Markets Day held –HexElect™ platform unveiled. First patients dosed in GEN3013 (DuoBody®-CD3xCD20) Phase I/II study in B-cell malignancies…
	21/11 16:02 af Jan Van de Winkel	Regulatory applications submitted in US and Europe for split dosing regimen and in China for relapsed/refractory MM. Positive CHMP opinion issued November 15, 2018…
	21/11 16:02 af Jan Van de Winkel	Positive topline results from Phase III CASSIOPEIA study combining daratumumab with bortezomib, thalidomide and dexamethasone (VTD) in frontline MM. Positive topline results from Phase III MAIA study combining daratumumab with lenalidomide and dexamethasone (DRd) in frontline MM…
	21/11 16:01 af Jan Van de Winkel	Darzalex approved in Europe in combination with bortezomib, melphalan and prednisone (VMP) in frontline multiple myeloma (MM)…
	21/11 16:01 af Jan Van de Winkel	Revenue DKK 1.789 bn up DKK 441 Mio. Expenses DKK 1.130 bn, up DKK 423 (or DKK 282 after reimbursement from partners). Operating result DKK 659 mio, up DKK 18 mio and net result DKK 638 mio, up DKK 320 mio…
	21/11 16:01 af Helge Larsen/PI-redaktør	Can you give us a short-term update on key figures and important events in Q3?
	21/11 16:00 af Jan Van de Winkel	We are deligthed to be chatting with you all and look forward to an energizing session.
	21/11 16:00 af Helge Larsen/PI-redaktør	Jan van de Winkel and David Eatwell. Welcome to Q & A here on ProInvestor.com We are very happy to have you back here and ready to answer questions from our Investors.
	21/11 15:57 af Helge Larsen/PI-redaktør	Great.
	21/11 15:56 af Jan Van de Winkel	We are here and eagerly awaiting your questions.
	21/11 15:55 af Helge Larsen/PI-redaktør	Jan and David. Are you online?
	21/11 14:27 af Helge Larsen/PI-redaktør	This session starts at 15 o'clock.